NALVANCANCT07636655
Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis
At risk: Primary completion moved 3 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date: Sep 1, 2026 to Dec 1, 2026
- Eligibility criteria expanded, about 8 words
- Primary and study completion pushed from Sep 1, 2051 to Dec 1, 2051
- Notable Start date: Jun 1, 2026 to Sep 1, 2026
- Primary and study completion pushed from Jun 1, 2051 to Sep 1, 2051
- Minor Secondary endpoints: 1 to 3v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
This cohort follows adult patients with ANCA-associated vasculitis, a systemic autoimmune disease. The intervention of interest is Rituximab (RTX) therapy, used to induce B-cell depletion. The study involves longitudinal monitoring with the systematic collection of biological samples at key time points: before treatment induction, during the depletion phase, and upon immune reconstitution (2 years after the last injection or at relapse). The objective is to study the pleiotropic effects of B-cell depletion on CD8+ T-cells to identify biomarkers capable of predicting the risk of relapse.
Other: systematic collection of additional biological samples (blood volume)
Diagnostic tests: BVAS (Birmingham Vasculitis Activity Score) and VDI (Vasculitis Damage Index)
Sites
1 site in 1 country
- CHU de NantesNantes, Loire-atlantique, France